FGFR4 activation has been associated with cancer progression and resistance to different types of anti-cancer therapy and preclinical studies have shown that FGFR4 knockdown or pharmacologic inhibition can inhibit tumor growth and metastasis both in vitro and in vivo (see58 for review). Here, FGFR4 is linked to neoplasm.